NeuroRX

Rapport Therapeutics

This company develops small molecule precision medicines for patients suffering from central nervous system disorders.

Neurocentrx Pharma Ltd

This biopharmaceutical company develops oral ketamine formulations to treat patients suffering from treatment-resistant mood disorders, neurodegenerative diseases, and complex pain conditions.

Syremis Therapeutics

This biopharmaceutical company develops small-molecule oral medicines for patients with neuropsychiatric conditions, including schizophrenia, major depressive disorder and bipolar depression.

Engrail Therapeutics

This company develops small-molecule therapies for patients with neurologic, neuropsychiatric and neurodevelopmental disorders such as anxiety, depression and rare diseases.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Neumora Therapeutics

This biopharmaceutical company develops medicines for patients with neuropsychiatric disorders and neurodegenerative diseases.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Syremis

This biopharmaceutical company develops oral small-molecule medicines for patients with schizophrenia, major depressive disorder, and other serious mental health conditions.